ALK B ALK-ABELLO A/S

Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025

Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025

ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its annual report for 2024 in the morning on Wednesday, 19 February 2025.

Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m. CET, where ALK’s management will comment on the results and outlook and be available for questions.

ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR. 

Live audio webcast

The meeting will be audio webcasted live and be available for replay on .

Conference call

If you wish to participate via telephone, please register for the conference call by using this link: and follow the instructions. You will receive an email from with dial-in details, including a passcode and a pin code. Please make sure to whitelist  and/or check your spam filter. We advise you to register on the day before the call at the latest.

Presentation

The presentation will be available on shortly before the meeting starts.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. , mobile

Media: Maiken Riise Andersen, tel.

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at

Attachment



EN
12/02/2025

Underlying

ALK BALK-ABELLO A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK opjusterer forventningerne til omsætningen i 2025

ALK opjusterer forventningerne til omsætningen i 2025 Intern viden ALK (ALKB:DC / OMX: ALK B) har i dag annonceret, at forventningerne til helåret er blevet opjusteret. Omsætningen forventes nu at stige med 12-14% i lokale valutaer (mod tidligere: 9-13% vækst).Forventningerne til EBIT-marginen er fortsat en stigning på 5 procentpoint til 25%. De opjusterede forventninger afspejler en højere omsætning end forventet i Europa i andet kvartal 2025 og bedre udsigter for resten af året. Andet kvartal var positivt påvirket af salget af adrenalin-autoinjektorer og momentum i table...

2h / 27m 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK upgrades its full-year revenue outlook

ALK upgrades its full-year revenue outlook Inside information ALK (ALKB:DC / OMX: ALK B) today announced that the 2025 full-year financial outlook has been upgraded. Revenue is now expected to grow by 12-14% in local currencies (previously 9-13% growth). The operating profit (EBIT) margin is still expected to improve by 5 percentage points to 25%. The updated outlook reflects higher-than-expected revenue in Europe in Q2 and an improved outlook for the rest of the year. Q2 was positively influenced by sales of adrenaline autoinjectors and by the momentum for tablets in Europe which i...

2h / 27m 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK’s tree pollen tablet (ITULAZAX®) now recommended by NICE for use i...

ALK’s tree pollen tablet (ITULAZAX®) now recommended by NICE for use in the UK health system ALK (ALKB:DC / OMX: ALK B) today announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of the company’s tree pollen tablet ITULAZAX® for the treatment in adults. The recommendation allows for patients to gain access to ITULAZAX® through the National Health Service (NHS) systems in England, Wales, and Northern Ireland by making it eligible for general reimbursement. The recommendation of ITULAZAX® is another significant milestone for ALK, marking the sec...

July 21, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

EURneffy® godkendt som den første nålefri behandling af anafylaksi hos...

EURneffy® godkendt som den første nålefri behandling af anafylaksi hos voksne og børn i Storbritannien Intern viden ALK (ALKB:DC / OMX: ALK B) har i dag annonceret, at det britiske Medicines and Healthcare Products Regulatory Agency (MHRA) har godkendt EURneffy® 2 mg til behandling af anafylaksi hos voksne og børn (≥30 kg) i Storbritannien. Lanceringen i Storbritannien ventes at ske inden for de kommende måneder, så snart forhandlinger om tilskud og prisfastsættelse er afsluttet. EURneffy® (varemærket for neffy® i EU og Storbritannien) er den første godkendte adrenalinnæsespray til akut...

July 18, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

EURneffy® approved as the first needle-free anaphylaxis treatment of a...

EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK Inside Information ALK (ALKB:DC / OMX: ALK B) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved EURneffy® 2 mg in the United Kingdom (UK) for anaphylaxis treatment of adults and children (≥30 kg). The market launch in the UK is expected within the coming months once market access negotiations are completed. EURneffy® (the trade name for neffy® in the EU and the UK) constitutes the first approved adrenaline nasal spray for timely emergency treatm...

July 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch